InvestorsHub Logo
Followers 6
Posts 137
Boards Moderated 0
Alias Born 11/27/2018

Re: VuBru post# 190439

Tuesday, 05/07/2019 11:00:34 PM

Tuesday, May 07, 2019 11:00:34 PM

Post# of 427038
Based on Canada NDS PR, sounds like they are looking for a pretty broad label...

“The NDS seeks an indication for promotion of Vascepa in Canada to reduce the risk of major adverse cardiovascular events (“MACE”) in statin-treated patients with elevated triglycerides and other risk factors...if approved, Vascepa will be the first drug approved in Canada for this indication.”
Volume:
Day Range:
Bid:
Ask:
Last Trade Time:
Total Trades:
  • 1D
  • 1M
  • 3M
  • 6M
  • 1Y
  • 5Y
Recent AMRN News